Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs

SUNNYVALE, California, September 14, 2010 - Molecular Devices, Inc., a long-time leader in bioanalytical systems for
microplate analysis, today announced the launch of two new multi-mode
detection platforms that expand its portfolio of microplate readers, enabling
the company to meet all combinations of customer needs now and into the
future.

    (Logo: photos.prnewswire.com/prnh/20100406/SF82092LOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20100406/SF82092LOGO)

Both products will be showcased at Miptec 2010, Switzerland, September
20-24, as well as several other 2010 shows including Het, Scanlab,
Biotechnica, SBS China, Society for Neuroscience, and American Society for
Cell Biology. Please check www.MolecularDevices.com for details.

The SpectraMax(R) Paradigm(R) Platform is the only user-upgradeable
multi-mode reader on the market today and is ideal for drug discovery
research, including high-throughput screening. The FilterMax(TM) F3 and F5
Series Readers deliver unmatched assay performance compared to similarly
priced readers and are ideal for a wide range of life science research
applications. Both platforms were developed in response to requests from
existing customers, and both are commercially available with shipping to
begin in early October.

"With these two new platforms, we now have an ideal microplate reader for
any combination of application, detection, and budget needs," said Mark
Verheyden, President of Molecular Devices. "We've carefully expanded our
portfolio to ensure that we will be able to meet our customers' needs across
ever-evolving research environments. By adding the SpectraMax Paradigm and
FilterMax(TM) F Series Platforms to our existing lines of readers, we now
offer the most comprehensive line of microplate readers on the market today."

Read What you Want When You Want with the SpectraMax Paradigm Multi-Mode
Microplate Reader

The new patent-pending SpectraMax Paradigm Platform is the only
multi-mode detection platform on the market today that allows users to
upgrade the functionality of their instrument directly-no service call, no
factory shipment. Upgrading is as easy as selecting from over 20
mix-and-match detection cartridges and inserting them into one or more of 12
instrument slots. A single cartridge can be changed in less than 2
minutes-the instrument can be fully reconfigured in 10 to 20 minutes. This
unmatched flexibility provides a platform that can easily be adapted to meet
constantly evolving application needs and ever advancing detection
technologies while accommodating most budgets. With multiple detection modes,
including AlphaScreen and HTRF, as well as 1536-well microplate compatibility
to support high-through screening, the SpectraMax Paradigm Reader is ideal
for drug discovery & development, particularly for assay development, lead
identification, and lead optimization.

Unmatched Assay Performance is Now Within the Reach of any Life Science
Laboratory with the new FilterMax F3 & F5 Multi-Mode Readers

The new, patented FilterMax F Series Platform delivers a unique
combination of value, performance, and sensitivity, putting high-performance
multi-detection capabilities into the hands of any life science researcher.
This unique filter-based platform delivers unmatched assay performance across
a broad range of life science applications, and currently offers two models:
the F3 with absorbance, fluorescence, and luminescence detection modes and
the F5 with those same modes plus fluorescence polarization and time resolved
fluorescence modes.

For more information, please visit www.moleculardevices.com, send
an email to info@moldev.com, or contact your local sales & support office.

About Molecular Devices: At Molecular Devices we have one focus-our
customers. When you become our customer, your needs drive our actions and
your success is our concern. Our instruments offer a full spectrum of
detection technologies and meet all throughput and content needs. Our goal is
to deliver highly relevant bioanalytical products to detect biology, decode
data, and drive discovery.

All products are FOR RESEARCH USE ONLY. Not for Use in Diagnostic
Procedures.

All trademarks are the property of Molecular Devices, Inc.

Lisa English, PhD, APR, Director of Communications of Molecular Devices, Inc., +1-408-747-3630, lisa.english at moldev.com